Patients’ baseline cannabinoid use is associated with an increased likelihood of requiring high doses of sedation for gastroscopy but not for colonoscopy, according to new research presented at Digestive Disease Week 2022.
High-dose midazolam (=5 mg IV; adjusted odds ratio [aOR], 2.89; 95% CI, 1.19-7.59) and use of IV diphenhydramine (aOR, 3.04; 95% CI, 1.29-7.30) was required for sedation for baseline cannabinoid users versus nonusers undergoing gastroscopy. Baseline cannabinoid use was